The prostate cancer genome: perspectives and potential. (Q38163225)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24239470 AND SRC:MED&resulttype=core&format=json

1 March 2020

title

The prostate cancer genome: perspectives and potential (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24239470 AND SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

13 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24239470 AND SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24239470 AND SRC:MED&resulttype=core&format=json

1 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24239470 AND SRC:MED&resulttype=core&format=json

1 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24239470 AND SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

53.e15-22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24239470 AND SRC:MED&resulttype=core&format=json

1 March 2020

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

The mutational landscape of lethal castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Integrative genomic profiling of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

The genomic complexity of primary human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Punctuated evolution of prostate cancer genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

New strategies in prostate cancer: translating genomics into the clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Common gene rearrangements in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Antibody-based detection of ERG rearrangement-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Correlation of urine TMPRSS2:ERG and PCA3 to ERG and total prostate cancer burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Distinct genomic aberrations associated with ERG rearranged prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

The role of SPINK1 in ETS rearrangement-negative prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

The mitochondrial and autosomal mutation landscapes of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Alterations of androgen receptor in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Overcoming mutation-based resistance to antiandrogens with rational drug design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Induced chromosomal proximity and gene fusions in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Pten dose dictates cancer progression in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Therapeutic targeting of SPINK1-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

Characterization of KRAS rearrangements in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

The polycomb group protein EZH2 is involved in progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.08.025

10.1016/J.UROLONC.2013.08.025

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24239470 AND SRC:MED&resulttype=core&format=json

1 March 2020

1 reference